BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
BRSYF 10.29.2024
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Earnings Call
About Gravity Analytica
Recent News
- 01.02.2025 - 15 Effective Ways to Cope with Seasonal Depression and Brighten Your Winter Days
- 12.12.2024 - BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
- 12.03.2024 - Understanding Depression in Older Adults: Challenges, Stigma, and Treatment with BrainsWay Deep TMS
Recent Filings
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Tuesday, November 12, 2024 |
| Time: | 8:30 AM Eastern Time |
| United States: | 1-877-300-8521 |
| International: | 1-412-317-6026 |
| Israel: | 1-80-921-2373 |
| Conference ID: | 10193781 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1693565&tp_key=866e8470ea |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website,https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMSTM) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visitwww.brainsway.com.
Contacts:
BrainsWay:Ido MaromChief Financial OfficerIdo.Marom@BrainsWay.com
Investors:Brian RitchieLifeSci Advisorsbritchie@lifesciadvisors.com
